Prolonged Treatment of Zollinger-Ellison Syndrome by Long-Acting Somatostatin

Bonfils, S; Ruszniewski, Philippe; Costil, Vanessa; Laucournet, Henri; Vatier, J; René, E; Mignon, M

doi:10.1016/s0140-6736(86)90905-0

Cited by 37 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…anti-inflammatory effects [35] and reduced mesenteric blood flow [36], octreotide has been applied in a wide variety of conditions related with secretory diarrhea, e.g. AIDS [37], graft-versus-host disease [38], diabetes mellitus [39], short bowel syndrome [40], postgastrectomy dumping syndrome [41], Zollinger-Ellison syndrome [42], infectious diarrhea (e.g. cholera) [43], and CT- [11, 12, 16] and RT-induced diarrhea [21].…”

Section: Discussionmentioning

confidence: 99%

Octreotide in the Management of Chemoradiotherapy-Induced Diarrhea Refractory to Loperamide in Patients with Rectal Carcinoma

Topkan

Karaoğlu

2006

Oncology

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of octreotide in the treatment of chemoradiotherapy (CRT)-induced diarrhea (CRTID) refractory to conventional loperamide treatment in this pilot study. Methods: Forty-two rectal carcinoma (T_3–4N_0–2M₀) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide. Eligible patients were treated with pelvic radiotherapy combined with bolus 5- fluorouracil CRT. Octreotide was administered subcutaneously, 150 µg three times daily, for 5 consecutive days. Only complete resolution of diarrhea was considered as therapeutic success. Results: Diarrhea mainly occurred in the first 4 weeks of CRT (83.3%) and completely resolved in 34 patients (80.9%) following octreotide administration. Mean time to response was 2.7 days: 27 patients (64%) responded during the first 3 days, and the remaining 7 (17%) on days 4 and 5. No significant side effect was reported. Eight patients (19.1%) with refractory diarrhea were hospitalized for additional treatment. No treatment delay was reported in complete responders, whereas an average 7.7-day delay was observed in refractory patients. Antidiarrheal treatment was administered on an outpatient basis in the response group, whereas refractory patients were hospitalized for an average of 8.8 days. Conclusion: Daily subcutaneous octreotide administration (150 µg t.i.d.) for 5 days is apparently an effective, tolerable treatment modality for concurrent CRTID refractory to loperamide.

show abstract

Section: Discussionmentioning

confidence: 99%

Octreotide in the Management of Chemoradiotherapy-Induced Diarrhea Refractory to Loperamide in Patients with Rectal Carcinoma

Topkan

Karaoğlu

2006

Oncology

View full text Add to dashboard Cite

show abstract

“…Several studies have reported that short-term administration of octreotide may reduce gastric acidity and serum gastrin levels in ZES [18][19][20][21][22][23]27,28]. However, very long-term treatment of ZES with octreotide had not been reported so far.…”

Section: Discussionmentioning

confidence: 99%

Long‐term treatment with octreotide in patients with the Zollinger‐ElIison syndrome

Ruszniewski

Ramdani

Cadiot

et al. 1993

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract. This study reports the effects of 4 and 5-year treatment with octreotide (200 pg sc bid) in the Zollinger-Ellison syndrome (ZES). No symptoms related to acid hypersecretion were observed in the four patients throughout the study, and upper GI endoscopy was normal. Basal acid output (BAO) measured 12 h after injection, was below 10 mmol h-' in three to four patients and previous ranitidine treatment was discontinued. In the fourth case (pretreatment BAO value: 11 5 mmol h-I), BAO progressively decreased to 42 mmol h-' after 5 years of octreotide treatment. At the end of the study, serum gastrin levels were 58.5% (30-68) of the pretreatment values and two patients had normal gastrin levels. Peak acid output (PAO) decreased markedly after 2,4 and 5 years, by 68% (35-89) suggesting that octreotide had exerted an antitrophic effect on parietal cell mass. Diffuse hyperplasia of fundic argyrophil cells present in two patients before octreotide, decreased during the treatment. Mean argyrophil cell density for all patients was not significantly modified. Antral gastrin-cell density was in the normal range. No long-term side effect of octreotide treatment was observed. Although octreotide may not be considered as a substitute for benzimidazoles in the treatment of ZES, its specific properties may be of therapeutic benefit in some ZES patients.

show abstract

“…Somatostatin has been useful in the treatment of secretory diarrhea related to various diseases such as Zollinger-Ellison syndrome [2], VernerMorrison syndrome [3,12], the carcinoid syndrome [5], glucagonomas [3], and ileostomy [18]. However, the native form of somatostatin has the disadvantage of a short half-life, necessitating intravenous administration [15].…”

Section: Pharmakologikamentioning

confidence: 99%

Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995

Füeßl¹,

Zoller²,

Kochen

et al. 1989

Klin Wochenschr

View full text Add to dashboard Cite

Prolonged Treatment of Zollinger-Ellison Syndrome by Long-Acting Somatostatin

Cited by 37 publications

References 2 publications

Octreotide in the Management of Chemoradiotherapy-Induced Diarrhea Refractory to Loperamide in Patients with Rectal Carcinoma

Octreotide in the Management of Chemoradiotherapy-Induced Diarrhea Refractory to Loperamide in Patients with Rectal Carcinoma

Long‐term treatment with octreotide in patients with the Zollinger‐ElIison syndrome

Treatment of secretory diarrhea in AIDS with the somatostatin analogue SMS 201-995

Contact Info

Product

Resources

About